Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Japanese approval for Biopten in PKU

July 17, 2008

Sym-001 studied in new phase II trial for ITP

July 17, 2008

Triolex studied in new phase II trial for type 2 diabetes

July 17, 2008

Actonel and Benet receive additional indication approval in Japan for Paget's disease

July 16, 2008

Oramed completes equity financing of USD 5 million through private placement

July 16, 2008

DiaMedica meets primary endpoint from phase II trial of DM-83 in type 2 diabetes

July 16, 2008

Novo Nordisk files NDA for liraglutide in Japan

July 16, 2008

Jerini receives European approval for Firazyr for hereditary angioedema

July 16, 2008

Recent patents disclose new treatment options for metabolic disorders

July 16, 2008

Edison's second-generation coenzyme Q10 analogue enters phase I clinical trials

July 15, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...